今天分享的是：2025年中国出口跨境电商发展趋势白皮书 报告共计：8页 中国出口跨境电商迈入价值创造新阶段 自主创新与AI赋能成关键引擎 近年来，中国出口跨境电商行业正经历从"价格竞争"到"价值创造"的深刻转型。根据《2025年中国出口跨境电商发展趋势白皮书》，随着全球消费市场尤其 是Z世代网购人群比例预计攀升至90.3%，中国卖家不再依赖低价策略，而是通过产品创新、技术升级和品牌建设，推动行业向高质量发展迈进。在供应 端，已有64%的中国卖家将选品重点转向全新品类或现有产品的迭代更新，35%的销量来自一年内新选品，显示出创新已成为出海增长的核心动力。 在产品创新方面，中国企业展现出强劲的自主研发实力与市场敏锐度。白皮书指出，超过88%的出海产品为自主创新，32%为全球首发品类，涵盖AI智能硬 件、新一代信息技术等前沿领域。品牌通过挖掘用户真实需求，从使用场景中提炼创新方向，例如推出免换水扫地机器人、口袋无人机、柔美机械键盘等产 品，不仅解决了传统产品的痛点，还开辟了全新细分市场。这些创新产品在亚马逊等平台上获得平均4.3分以上的用户评价，超过60%的品牌产品斩获国际 奖项，显示出全球消费者对中国智造的认可。 ...

Core Insights - The Chinese pharmaceutical industry is entering a critical phase characterized by "innovation realization and global expansion," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - Companies are actively exploring diversified overseas pathways, with a focus on innovation commercialization, global breakthroughs, policy optimization, and opportunities for industry mergers and acquisitions by 2026 [1] Index Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.9% [1] - The China Securities Hong Kong Stock Connect Medical and Health Comprehensive Index increased by 1.0% [1] - The China Securities Innovative Drug Industry Index decreased by 0.2% [2] - The China Securities Biotechnology Theme Index fell by 0.6% [1] - The CSI 300 Medical and Health Index declined by 0.7% [1] ETF Details - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which focuses on innovative drug companies in Hong Kong [2] - The index consists of no more than 40 stocks involved in innovative drug research, development, and production, with a rolling P/E ratio of 58.2 times [2] - The China Securities Hong Kong Stock Connect Medical and Health Comprehensive Index includes 50 stocks from the medical device, biopharmaceutical, and chemical drug sectors, with a rolling P/E ratio of 28.3 times [2] - The China Securities Innovative Drug Industry Index focuses on A-share innovative drug leaders, comprising no more than 50 stocks, with a rolling P/E ratio of 49.9 times [2] - The China Securities Biotechnology Theme Index includes up to 50 stocks in gene diagnostics, biopharmaceuticals, and blood products, with a rolling P/E ratio of 54.8 times [3] - The CSI 300 Medical and Health Index covers companies in the medical and health sector, with a rolling P/E ratio of 30.7 times [3]

人民财讯11月20日电，中信建投（601066）发布医药生物2026年投资策略：中国医药产业迈入"创新兑 现+全球布局"的关键阶段，人口与内需基数、全产业链制造能力构成核心支撑，企业积极探索多元化 的出海路径。面对全球竞争与政策深化，行业需"立足于内、创新引领、开拓于外"，对内强化供应链安 全与合规能力，对外深化多元化出海布局。展望2026年，重点把握创新商业化、全球化突破、政策优化 带来的新增量及行业并购整合的机遇。 ...

新华财经南京11月19日电（记者王小璐）在全球经济格局深度调整、产业链重构加速的背景下，我国不 锈钢行业正经历价格下行、利润收缩与供需再平衡的挑战。在18日召开的2025（第七届）不锈钢及关键 金属材料高峰论坛上，与会专家指出，当前不锈钢价格已触及历史低位，而镍原料端成本支撑逐步显 现，行业亟需通过高端化转型与全球化布局开拓新发展空间。 多重因素影响不锈钢价格跌至近年低位、考验成本支撑 当前，不锈钢市场正面临严峻挑战。中国钢铁工业协会不锈钢分会执行会长张志方指出，随着全球经济 格局深度调整，当前国内不锈钢企业受原料价格波动以及国际竞争的影响，企业经营承压。而不锈钢下 游传统领域需求也在趋缓，供需矛盾凸显。 不可否认的是，近几年战略新兴产业的快速发展，也在给不锈钢行业带来新的机会。张志方强调，人工 智能、新能源装备、海洋工业等战略性新兴产业的快速发展，正为不锈钢及关键金属材料开辟新的应 用"蓝海"。面向未来，不锈钢及关键金属材料行业应聚焦核心技术的攻关，不断提升产品附加值，同时 积极开拓新市场，紧紧抓住海洋工程、新型储能、高端装备等带来的新的增长点，拓展不锈钢以及关键 技术的应用领域。在产业链发展方面，行业需加 ...

Core Viewpoint - The recognition of Seres as a "Best Practice Case" for corporate governance by the China Listed Companies Association highlights the company's effective governance mechanisms and operational efficiency, reinforcing its commitment to high-quality development and value sharing with stakeholders [1][3]. Group 1: Corporate Governance - The "Best Practice Case" award aims to promote compliance and effective operation of listed company boards, enhancing governance efficiency and demonstrating exemplary practices [3]. - Seres' selection for this award reflects high recognition from regulatory bodies and the capital market regarding its governance standards [3]. Group 2: Financial Performance - In the first three quarters of 2025, Seres achieved a revenue of 110.534 billion yuan and a net profit attributable to shareholders of 5.312 billion yuan, marking a year-on-year growth of 31.56% [3]. - As of October 2025, Seres has sold a total of 356,085 electric vehicles [3]. Group 3: Market Position and Expansion - On November 5, Seres successfully listed on the Hong Kong Stock Exchange, becoming the first luxury electric vehicle company to be dual-listed in both A-share and H-share markets [3]. - This dual listing is expected to inject strong international capital into the company, aiding in technological innovation and global expansion, thereby enhancing its global competitiveness and brand influence [3].

Core Insights - The opening of Noli's new European headquarters in Germany marks a significant step in the company's strategy to deepen its market presence in Europe and fulfill its long-term service commitments [1][3] - Noli aims to enhance local service systems, optimize global capacity, and strengthen R&D innovation to provide comprehensive customer service throughout the product lifecycle, thereby building core competitiveness beyond price [3] Company Strategy - Noli plans to establish strategic partnerships with distributors based on long-term cooperation, focusing on understanding customer needs and accurately matching business scenarios to drive significant sales growth in the European market [3][4] - The new headquarters will serve as a crucial spare parts center and after-sales service hub, with a doubled warehouse area and ample future development capacity to improve service efficiency for EU customers [4] Product and Service Development - Noli's product line includes material handling equipment (including AGVs), aerial work platforms, and cleaning equipment (including automation devices), which will be fully supported to enhance product sales in Europe [3][4] - The company will launch a combined online and offline product technology training program in 2026 to empower distributor teams and improve service capabilities and response efficiency in the European region [4] Global Network Expansion - Noli has established two factories, seven sales subsidiaries (including technical and parts centers), and over 200 distribution and service networks overseas, with plans to continue enhancing its global business network [4] - The new European headquarters will act as a pivot to strengthen global supply chain resilience and provide more integrated logistics solutions, contributing to the upgrade of the global logistics industry [4]

Core Viewpoint - Sanofi Bio showcased its new generation Continuous Glucose Monitoring System (CGM) at the 8th China International Import Expo, highlighting its advancements in diabetes digital management [1][3]. Group 1: Product Innovations - The Sanofi Aikan CGM is based on third-generation glucose sensing technology, reducing product size by 60%, enhancing comfort and concealment [3]. - The sensor's accuracy has reached international leading levels, with improved anti-interference performance and a battery life extended to 15 days, providing a comprehensive glucose fluctuation profile [3]. - The product has received EU CE-MDR certification and is currently pursuing FDA registration in the U.S. [3]. Group 2: Market Strategy - Sanofi Bio has integrated Trividia to leverage its established brand and channel resources, successfully entering mainstream retail systems like Walmart and Amazon [4]. - The company exports an average of 40,000 devices monthly to over 40 countries in Africa, targeting both grassroots healthcare and home users [4]. - Sanofi Bio ranks as the fourth largest blood glucose meter company globally and holds the top position in the Chinese market [4]. Group 3: Collaborative Ecosystem - Sanofi Bio participated in the Sanofi Type 1 Diabetes Ecosystem Cooperation Forum, discussing new diabetes management ecosystems with representatives from various sectors [4]. - The company emphasizes a multi-party collaboration model involving government, industry, academia, healthcare, and investment to create a sustainable diabetes management ecosystem [4][5]. - The integration of rapid testing capabilities, continuous data collection, and personalized analysis through the SinoGPT AI system aims to cover the entire diabetes management process from screening to long-term management [5]. Group 4: Future Vision - Sanofi Bio aims to become a global leader in diabetes digital management, focusing on innovation in medical technology to enhance health outcomes across diverse demographics [5].

Core Insights - The article emphasizes the strategic importance of the Chinese market for multinational companies, particularly for Zeiss, which views China as a key driver of global innovation and supply chain development [1][2] - Zeiss has achieved significant engagement at the China International Import Expo (CIIE), with intentions exceeding 400 million RMB this year [1][8] Company Strategy - Zeiss has been actively increasing its investment in China, focusing on local innovation and expanding its manufacturing and R&D capabilities in the Yangtze River Delta region [4][5] - The company plans to establish a comprehensive headquarters in Shanghai, covering 60 acres with an investment exceeding 600 million RMB, expected to be operational by 2027 [4][5] Market Performance - China has become Zeiss's largest single market globally since 2021, with revenue reaching 15.1 billion RMB in the 2023/24 fiscal year, accounting for nearly 20% of the company's total business [7] - The demand for high-end manufacturing, semiconductors, and life sciences in China continues to grow, providing ample opportunities for Zeiss's products [7] Competitive Landscape - The company acknowledges the increasing competition from local brands and emphasizes the need to participate in the market like a local enterprise, focusing on R&D and innovation speed as key competitive factors [8] - Zeiss has adapted its global distribution strategy to mitigate risks from geopolitical tensions, including localizing more production in China and shifting some manufacturing from the U.S. to Europe [8]

Group 1: 华勤技术 (603296.SH) - The company achieved a revenue of 128.82 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 70% [7] - The net profit attributable to shareholders reached 3.099 billion yuan, up 51% year-on-year [7] - The company’s gross margin improved to 8.17% in Q3 2025, an increase of 1.04 percentage points from Q2 2025 [7] - The company is expanding its global manufacturing layout, achieving large-scale shipments in India and Vietnam [8] - The multi-category business strategy is expected to drive significant performance growth, with projected net profits of 4.15 billion yuan, 5.15 billion yuan, and 6.17 billion yuan from 2025 to 2027 [8] Group 2: 汉朔科技 (301275.SZ) - The company reported a revenue of 2.809 billion yuan in the first three quarters of 2025, a decrease of 11% year-on-year [10] - The net profit attributable to shareholders was 314 million yuan, down 41% year-on-year [10] - The gross margin for Q3 2025 was 35.94%, an increase of 5.23 percentage points from Q2 2025, indicating a recovery in profitability [10] - The company is focusing on digitalization in the retail sector, with a business model centered around electronic price tag systems and SaaS cloud platform services [11] - Projected revenues for 2025 to 2027 are 4.056 billion yuan, 4.787 billion yuan, and 5.747 billion yuan, respectively [11] Group 3: 天山电子 (301379.SZ) - The company achieved a revenue of 1.338 billion yuan in the first three quarters of 2025, a year-on-year increase of 26.48% [12] - The net profit attributable to shareholders was 113 million yuan, up 7.75% year-on-year [12] - The company is strategically investing in the storage sector, aiming to create a complete storage ecosystem [13] - The projected revenues for 2025 to 2027 are 1.978 billion yuan, 2.546 billion yuan, and 2.893 billion yuan, respectively [13] Group 4: 恒瑞医药 (600276.SH) - The company reported a revenue of 23.188 billion yuan in the first three quarters of 2025, representing a 14.85% increase [15] - The net profit attributable to shareholders was 5.751 billion yuan, up 24.50% year-on-year [15] - The company is accelerating its internationalization efforts, with multiple overseas collaborations and licensing agreements [16] - The projected net profits for 2025 to 2027 are 8.8 billion yuan, 10.28 billion yuan, and 12.15 billion yuan, respectively [18] Group 5: 益丰药房 (603939.SH) - The company achieved a revenue of 17.286 billion yuan in the first three quarters of 2025, a slight increase of 0.39% [20] - The net profit attributable to shareholders was 1.225 billion yuan, up 10.27% year-on-year [20] - The company is focusing on non-pharmaceutical innovations, which are expected to drive growth in the future [21] - The company plans to optimize its store network and expand its franchise business, with a total of 14,666 stores as of Q3 2025 [21] Group 6: 中兴通讯 (000063.SZ) - The company reported a revenue of 100.52 billion yuan in the first three quarters of 2025, a year-on-year increase of 11.63% [23] - The net profit attributable to shareholders was 5.32 billion yuan, down 32.7% year-on-year [23] - The company is experiencing pressure in its operator business, but its computing power segment is showing significant growth [24] - The projected net profits for 2025 to 2027 are 7.4 billion yuan, 8.5 billion yuan, and 10 billion yuan, respectively [24] Group 7: 德科立 (688205.SH) - The company achieved a revenue of 6.5 billion yuan in the first three quarters of 2025, a year-on-year increase of 8.6% [26] - The net profit attributable to shareholders was 40 million yuan, down 47.4% year-on-year [26] - The company is focusing on DCI (Data Center Interconnect) products, which are experiencing accelerated growth [27] - The projected net profits for 2025 to 2027 are 70 million yuan, 250 million yuan, and 410 million yuan, respectively [27] Group 8: 北新建材 (000786.SZ) - The company reported a revenue of 19.905 billion yuan in the first three quarters of 2025, a decrease of 2.25% year-on-year [29] - The net profit attributable to shareholders was 2.586 billion yuan, down 17.77% year-on-year [29] - The company is facing challenges in its gypsum board business but is seeing growth in its other segments [30] - The projected net profits for 2025 to 2027 are 3.364 billion yuan, 3.959 billion yuan, and 4.432 billion yuan, respectively [32]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 29.17 CNY, reflecting a 15x PE for 2025 [4][7]. Core Views - The company's main business of gypsum board continues to face pressure, with a 17.8% year-on-year decline in net profit for the first three quarters, totaling 2.59 billion CNY [1]. - Despite the challenges in the gypsum board segment, the company is experiencing growth in its two wings of business, particularly in waterproofing and coatings, benefiting from an increase in market share [2]. - The company is focusing on a strategy that combines organic growth with external expansion, aiming for high-quality development in niche markets [2]. Financial Performance - For the first three quarters, the company reported revenues of 19.91 billion CNY, a decrease of 2.3% year-on-year, and a net profit of 2.59 billion CNY, down 17.8% [1]. - The gross margin for the first three quarters was 29.5%, a decline of 1.2 percentage points year-on-year, with a net margin of 13.3%, down 2.4 percentage points [3]. - Operating cash flow for the first three quarters was 1.54 billion CNY, a decrease of 43.1% year-on-year, although the decline in Q3 was less severe at 13.3% [3]. Market Conditions - The price of gypsum board is expected to continue declining due to sustained pressure on demand, with a 16.8% year-on-year drop in housing completion area impacting demand [2]. - The company is implementing product upgrades and expanding into home decoration and rural markets to mitigate market decline and stabilize prices [2]. Future Outlook - The company has revised its net profit forecasts for 2025-2027 to 3.31 billion CNY, 3.86 billion CNY, and 4.41 billion CNY, respectively, reflecting adjustments due to the declining gypsum board prices [4]. - The report emphasizes the potential for the company's "one body, two wings" strategy to yield positive results in the future [4].